Skip to main content

Table 1 Final selected attributes and their levels

From: Public and decision-maker stated preferences for pharmaceutical subsidy decisions in Iran: an application of the discrete choice experiment

Attributes

Levels

The severity of disease without treatment

Moderate, severe, without changing in quality of life (QoL)

Health gain after treatment

Relative health, full health

Prevalence of the disease

Rare, not rare

Cost of treatment per patient for a month

Less than 1000,000 Rial (< US$ 30)*; 100,000–2000,000 Rial (US$ 30-60); 2000,000–5000,000 Rial (US$ 60-150); more than 5000,000 Rial (> US$ 150)

  1. *Based on mean currency exchange rate in 2017 according to Central bank of Iran (https://www.cbi.ir/exrates/rates_fa.aspx, access date 04.05.2018)